Changes of CD68,TGF-β2 and VEGF levels in benign prostatic hyperplasia and their clinical value
Objective To analyze the changes of cluster of differentiation 68(CD68),transform-ing growth factor β2(TGF-β2)and vascular endothelial growth factor(VEGF)levels in benign prostatic hy-perplasia(BPH)and preliminary clinical study.Methods 207 cases of benign prostatic hyperplasia patients(observation group)who were treated in our hospital from January 2020 to December 2022 were selected as the study objects,and 150 cases of middle-aged and elderly men who underwent healthy physical examination during the same period were selected as control group.The levels of serum CD68,TGF-β2,and VEGF were compared between the two groups;the levels of CD68,TGF-β2,and VEGF in patients with different degrees of BPH in the observation group were compared.The Kappa consistency test was used to evaluate the consis-tency of serum CD68,TGF-β2,VEGF alone or combined diagnosis of BPH and pathological biopsy results.The ROC curve was drawn to analyze the value of serum CD68,TGF-β2,and VEGF alone and in combina-tion in diagnosing BPH.Results The levels of serum CD68,TGF-β2,and VEGE in the control group were lower than those in the observation group,and the difference was statistically significant(P<0.05).Serum CD68,TGF-β2,and VEGE levels in the observation group:GradeⅢ>GradeⅡ>GradeⅠ,and the differ-ence was statistically significant(P<0.05).The Kappa values of serum CD68,TGF-β2,and VEGF alone and in combination for the diagnosis of BPH and pathological biopsy results were 0.536,0.617,0.631,and 0.878,respectively.The AUC of the combination of serum CD68,TGF-β2,and VEGF for the diagnosis of BPH was 0.812,which was higher than the three indicators are detected separately(P<0.05).Conclusion The de-velopment of BPH can be understood by detecting changes in serum CD68,TGF-β2,and VEGF levels.These three indicators are beneficial to clinical early diagnosis and prognosis assessment of patients.
NETL
NSTL
万方数据
维普
